Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients
Public ClinicalTrials.gov record NCT01063829. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aim of the study is to find out whether AIC246 is safe and efficacious in lowering the chances of the cytomegalovirus becoming active again and causing illness after an HBPC transplant (allogeneic stem cell transplant).
Study identification
- NCT ID
- NCT01063829
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 133 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2010 (Type not available)
- Primary completion
- Oct 2011 (Actual)
- Completion
- Dec 2011 (Actual)
- Last update posted
- Feb 13, 2018
2010 – 2011
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Medical Center | Los Angeles | California | — | — |
| Stanford University Hospital | Stanford | California | — | — |
| Denver St. Lukes Presbyterian | Denver | Colorado | — | — |
| University of Florida | Gainesville | Florida | — | — |
| University of Chicago Medical Center | Chicago | Illinois | — | — |
| Loyola University Chicago | Maywood | Illinois | — | — |
| Indiana BMT | Beech Grove | Indiana | — | — |
| University Of Iowa | Iowa City | Iowa | — | — |
| Dana Farber Cancer Institute, | Boston | Massachusetts | — | — |
| Karmanos Cancer Institute | Detroit | Michigan | — | — |
| University of Minnesota | Minneapolis | Minnesota | — | — |
| Jeanes Hospital of TUHS | Philadelphia | Pennsylvania | — | — |
| UPMC Cancer Center | Pittsburgh | Pennsylvania | — | — |
| MD Anderson Cancer Center | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01063829, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 13, 2018 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01063829 live on ClinicalTrials.gov.